BELFAST, Northern Ireland, June 30, 2026
Cumulus Neuroscience has announced the publication of new findings in Frontiers in Digital Health demonstrating that its NeuLogiq® Platform is feasible, well tolerated, and highly usable for at-home cognitive and electroencephalography (EEG) assessment in people living with mild Alzheimer’s disease dementia. The results from the CNS-101 study mark the first successful deployment of the digital biomarker platform in patients diagnosed with Alzheimer’s disease and highlight its potential to transform the way clinical trials measure disease progression. By combining wireless EEG monitoring, tablet-based cognitive testing, sleep assessments, and cloud-based digital analytics, the NeuLogiq Platform provides objective, real-world measurements of brain function from patients’ homes, reducing reliance on traditional clinic-based assessments that often fail to detect subtle cognitive changes. The publication represents a significant advance in digital neurology and supports the growing adoption of decentralized technologies designed to improve the efficiency, sensitivity, and patient experience of Alzheimer’s disease clinical research.
Home-Based Digital Biomarkers Demonstrate High Patient Adherence
The CNS-101 study enrolled 119 participants, including 59 individuals with mild Alzheimer’s disease dementia and 60 age-matched healthy controls, across seven clinical sites in the United Kingdom. Following a single supervised training session, participants independently completed wireless EEG recordings and tablet-based neurocognitive assessments at home over a demanding 52-week study period. Results showed exceptional engagement, with patients living with Alzheimer’s disease completing 99.7% of all initiated assessment sessions while maintaining 77% overall adherence throughout the year-long protocol. Healthy control participants achieved an even higher adherence rate of 88.8%, substantially exceeding adherence rates reported in previous home-monitoring studies involving older adults.
Researchers found that participants were able to integrate assessments into their daily routines with minimal burden, despite the presence of mild dementia, demonstrating the practicality of collecting objective digital biomarkers outside traditional healthcare settings. These findings suggest that frequent, home-based monitoring can provide more continuous and reliable measurements of cognitive performance than conventional clinic visits while improving participant convenience and long-term study retention.
Digital Neurology Platform Could Transform Alzheimer’s Clinical Trials
Advertisement
Current Alzheimer’s disease clinical trials primarily depend on clinician-administered cognitive assessments, including the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating (CDR) scale. These traditional evaluations provide only occasional snapshots of patient performance and may be influenced by examiner variability, limiting their sensitivity for detecting subtle disease progression or treatment response. The NeuLogiq® Platform was specifically developed in collaboration with ten leading global pharmaceutical companies to address these limitations through objective, high-frequency measurements spanning EEG, cognition, mood, speech, and sleep.
Investigators believe that collecting repeated digital biomarkers in patients’ natural home environments may significantly improve the precision of disease monitoring while reducing the need for frequent hospital visits. More sensitive endpoints could enable smaller, shorter, and more cost-effective Alzheimer’s clinical trials, accelerating the development of disease-modifying therapies while reducing the burden placed on patients, caregivers, and healthcare providers.
Publication Supports Next Generation of Precision Neurology
The publication further strengthens Cumulus Neuroscience’s mission to advance AI-enabled digital biomarkers for neurological and neuropsychiatric disorders. The NeuLogiq® Platform integrates an FDA 510(k)-cleared wireless dry-sensor EEG headset, validated cognitive assessments, cloud-based analytics, and machine learning algorithms to provide continuous, objective evaluation of brain function across multiple disease areas. Beyond Alzheimer’s disease, the platform is being developed to support research involving depression, schizophrenia, and other central nervous system disorders, helping pharmaceutical companies improve clinical trial decision-making and accelerate therapeutic development.
As decentralized clinical trials continue expanding worldwide, the successful year-long deployment of NeuLogiq in patients with Alzheimer’s disease demonstrates that advanced digital technologies can deliver reliable, patient-centered endpoints capable of transforming neuroscience research and improving the future development of innovative CNS therapies.
Source: Cumulus Neuroscience press release
